Medicinal and edible composition for relieving central fatigue as well as preparation method and application thereof
Through the enzymatic extraction of ginseng and ginger, the drug to relieve central fatigue is prepared by using the enzymatic extraction of ginseng and ginger, which solves the side effects and poor effects of central fatigue treatment in the prior art, and achieves safe and effective central fatigue relief. It has synergistic effect.
Patent Information
- Application Number
- CN202411149396.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art lacks special drugs that effectively relieve central fatigue, and chemical drugs have side effects, which cannot truly solve the problems of energy substance depletion and metabolites accumulation.
Using medicinal and food homologous compositions, including ginseng and ginger, water-soluble powder preparations are prepared through enzymatic extraction and drying treatment to relieve central fatigue and improve the content of the brain-entering ingredients according to the principle of traditional Chinese medicine.
Significantly improve central fatigue, increase the content of glutamate in the brain, reduce the content of the inhibitory transmitter γ-aminobutyric acid, reduce the incubation period of the Barnes maze, increase the correct alternation rate of T maze, and has small side effects. Dosage form Diverse and easy to use.
Smart Images

Figure CN118987153A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a medicine-food homologous composition for relieving central nervous system fatigue, and a preparation method and application thereof. Background Art
[0002] Central fatigue refers to the process in which changes in the central nervous system due to physical or mental factors cause decreased muscle function, cognitive decline, or abnormal mood changes. With the increasing pressure in work and life, fatigue has become one of the main reasons affecting human physical and mental health. Peripheral fatigue is no longer the main fatigue that plagues people's lives, and central fatigue caused by multiple internal and external factors is the type of fatigue that greatly affects people's work efficiency and quality of life. As the pace of society continues to accelerate, people's work pressure and work intensity continue to increase, and more and more people are troubled by fatigue. A 2021 survey showed that due to the impact of the epidemic, the incidence of fatigue among medical workers reached 36.5%, and fatigue was highly correlated with depression.
[0003] At present, for eliminating fatigue, especially central fatigue, there is no ideal specific medicine on the market. Now often use some chemical drugs, such as amphetamine, caffeine, sympathomimetic stimulants, etc. to relieve fatigue, but these drug mechanisms of action are mainly concentrated in the excitation center, relieving the fatigue caused by central inhibition, which does not solve the problems caused by energy material exhaustion, metabolite accumulation, etc., so chemical drugs only create the "illusion" of fatigue relief, and do not really relieve fatigue. And these chemical drugs also have side effects such as addiction, hepatotoxicity and central toxicity. Although patent CN116687987A discloses a Chinese medicine composition prepared with ginseng and angelica as raw materials to relieve central fatigue, angelica enters the liver, heart, spleen meridians, and mainly treats blood tonification and blood circulation. It is impossible to cooperate with ginseng to break through the blood-brain barrier, and the brain component and anti-central fatigue effect are limited. Summary of the invention
[0004] In order to solve the technical problem that there is no specific medicine on the market to eliminate or relieve central nervous system fatigue, and the existing chemical drugs for relieving central nervous system fatigue have large side effects. Based on the concept of "medicine and food are of the same origin", the present invention provides a medicine and food composition, medicine and food preparation, and preparation method and application thereof that can relieve central nervous system fatigue, so as to relieve central nervous system fatigue on a safe and effective basis.
[0005] The objective of the present invention is achieved through the following technical solutions:
[0006] On the one hand, the present invention provides a medicine-food composition for relieving central fatigue. The raw materials of the composition include 4.5 to 18 parts of ginseng and 3 to 12 parts of ginger by weight.
[0007] In another aspect, the present invention provides a medicine-food preparation, which is prepared from the medicine-food composition described above.
[0008] Preferably, the dosage form of the medicine-food homologous preparation includes at least one of a decoction piece, a decoction, a powder, an oral solution, an ointment, a granule, a tablet, a capsule or an alcoholic preparation.
[0009] On the other hand, the present invention provides a method for preparing the above-mentioned medicine-food preparation, which comprises: first drying, crushing and screening the raw materials to obtain fine powder; mixing the enzyme preparation and water with the fine powder, performing heat preservation enzymatic extraction, and then heating for re-extraction, and then centrifuging and filtering to obtain a filtrate; finally, concentrating, sterilizing and second drying the filtrate to obtain.
[0010] Preferably, the enzyme preparation comprises Viscozyme L and β-glucanase.
[0011] More preferably, the mass concentration of Viscozyme L is 1%.
[0012] More preferably, the mass concentration of the β-glucanase is 1%.
[0013] Preferably, the mass ratio of the enzyme preparation, the water and the fine powder is 1:500-1000:50-100.
[0014] More preferably, the mass ratio of the enzyme preparation, the water and the fine powder is 1:1000:100.
[0015] Preferably, the temperature of the heat preservation enzymatic extraction is 45 to 55° C., and the time of the heat preservation enzymatic extraction is 1 to 3 hours.
[0016] More preferably, the temperature of the heat preservation enzymatic extraction is 50° C., and the time of the heat preservation enzymatic extraction is 2 h.
[0017] Preferably, the temperature of the re-extraction is 75-85° C., and the time of the re-extraction is 1-3 hours.
[0018] More preferably, the temperature of the re-extraction is 80° C., and the time of the re-extraction is 1 hour.
[0019] Preferably, the screening comprises: passing through a 40-60 mesh sieve.
[0020] More preferably, the screening comprises: passing through a 60-mesh sieve.
[0021] More preferably, the second drying comprises spray drying.
[0022] In another aspect, the present invention provides use of the above-mentioned medicine-food homologous composition, medicine-food homologous preparation or the described method in the preparation of medicines and / or health products and / or foods for relieving or improving central fatigue.
[0023] Beneficial effects:
[0024] (1) The Chinese medicine combination of the present invention uses herbs that are both medicinal and edible, follows the principle of Chinese medicine compatibility, and is based on the understanding and treatment principles of traditional Chinese medicine on the pathogenesis of fatigue. Ginseng is used as the main ingredient, which is sweet, warm, and invigorates the qi, strengthens the spleen and nourishes the stomach; ginger is the most commonly used Chinese medicine and edible spice that can be used as both food and medicine. The compatibility of ginseng and ginger can increase the content of ginseng's components that relieve brain function and improve the efficacy of ginseng in relieving central fatigue.
[0025] (2) The medicine-food composition of the present invention can relieve exercise-induced central nervous system fatigue. The composition is a spray-dried powder with stable properties, long shelf life, and is completely soluble in water.
[0026] (3) The edible-medicinal composition of the present invention has a simple production method and can be made into pharmaceutically acceptable dosage forms, such as capsules, granules, oral liquids, etc. It is easy to use, has high quality, less pollution, and less side effects; and it is easy to transport and carry when made into capsules.
[0027] (4) Experiments have shown that the food-drug combination of the present invention can significantly improve central nervous system fatigue in mice, reduce the latency of entering a hole in the Barnes maze, increase the correct alternation rate in the T maze, increase the content of the excitatory neurotransmitter glutamate (Glu) in the brain, and reduce the content of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) in the brain. It can be seen that the food-drug combination of the present invention has the function of alleviating central nervous system fatigue in mice.
[0028] (5) Comparative experiments have confirmed that the ingredients of the food-drug combination of the present invention are coordinated with each other and their function of jointly relieving central nervous system fatigue is superior to that of any of the Chinese medicines in the combination used alone, thus having a synergistic effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 This is the experimental example of the effect of the Chinese medicine and food compound on the hole-finding time of the Barnes maze (A) and the correct alternation rate of the T maze (B) in fatigued mice.
[0030] Figure 2 This is the experimental example of the effect of the Chinese medicine and food compound on the Glu / GABA ratio (A), 5-HT (B) and eNOS (C) levels in the brain tissue of fatigue mice.
[0031] Figure 3 This is an experimental example of the effect of a Chinese medicinal and edible compound on the brain-entering components of ginseng, panaxatriol (A) and 20(S)-protopanaxadiol (B).
[0032] exist Figure 1 and 2 In the table, * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and **** indicates P < 0.0001. DETAILED DESCRIPTION
[0033] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clear, the present application is further described in detail below in combination with the implementation methods. Unless otherwise defined, all scientific and technological terms used herein have the same meanings as understood by ordinary technicians in the field.
[0034] In an embodiment of the present invention, the present invention provides a medicinal and edible composition for relieving central fatigue, comprising the following raw materials in a weight ratio: 4.5 to 18 parts of ginseng and 3 to 12 parts of ginger.
[0035] In some embodiments, the edible and medicinal composition for relieving central nervous system fatigue comprises the following raw materials in the following weight ratio: 9 parts of ginseng and 6 parts of ginger.
[0036] In an embodiment of the present invention, a medicine-food preparation is provided, wherein the preparation is prepared from the medicine-food composition described in any one of the above embodiments.
[0037] In some embodiments, the dosage form of the preparation includes at least one of a decoction, a decoction, a powder, an oral solution, an ointment, a granule, a tablet, a capsule or an alcoholic preparation.
[0038] In some examples, the dosage form of the preparation includes at least one of oral solution, capsule or granule.
[0039] In the above-mentioned medicine-food composition or preparation of the present invention, various drugs are used together in accordance with the compatibility principle of "monarch, minister, assistant and envoy" in traditional Chinese medicine, based on the understanding and treatment principles of the pathogenesis of fatigue in traditional Chinese medicine, with ginseng as the monarch, sweet and warm, invigorating qi, strengthening the spleen and nourishing the stomach; ginger is mainly used to open up the mind, and the ginseng-ginger drug pair is used to increase the content of ginseng's components that relieve brain function, so as to achieve the effect of relieving central fatigue.
[0040] In an embodiment of the present invention, the present invention also provides a method for preparing the above-mentioned medicine-food preparation for relieving central fatigue, comprising the following steps:
[0041] 4.5 to 18 parts of ginseng and 3 to 12 parts of ginger are weighed according to a ratio, and then subjected to a first drying, crushing and sieving to obtain fine powder. An enzyme preparation and water are mixed with the fine powder, and the powder is subjected to heat preservation and enzymatic extraction, and then the temperature is increased for re-extraction, and then centrifuged and filtered to obtain a filtrate. Finally, the filtrate is concentrated, sterilized and dried for a second time to obtain the medicine-food preparation.
[0042] In some embodiments, the enzyme preparation includes Viscozyme L and β-glucanase. Viscozyme L and β-glucanase are selected to destroy plant cell walls and increase the yield of effective ingredients.
[0043] In some examples, the mass concentration of Viscozyme L is 1%.
[0044] In some examples, the mass concentration of the β-glucanase is 1%.
[0045] In some embodiments, the mass ratio of the enzyme preparation, the water and the fine powder is 1:500-1000:50-100.
[0046] In some examples, the mass ratio of the enzyme preparation, the water, and the fine powder is 1:1000:100.
[0047] In some embodiments, the temperature of the heat preservation enzymatic extraction is 45 to 55° C., and the time of the heat preservation enzymatic extraction is 1 to 3 hours.
[0048] In some examples, the temperature of the incubation enzymatic extraction is 50° C., and the time of the incubation enzymatic extraction is 2 hours.
[0049] In some embodiments, the temperature of the re-extraction is 75-85° C., and the time of the re-extraction is 1-3 hours. After the enzymatic hydrolysis, the re-extraction is performed at a higher temperature to increase the yield of the effective components.
[0050] In some examples, the re-extraction temperature is 80° C., and the re-extraction time is 1 hour.
[0051] In some embodiments, the screening includes: passing through a 40-60 mesh sieve.
[0052] In some examples, the screening includes: passing through a 60-mesh screen.
[0053] In some examples, the second drying includes spray drying.
[0054] Specific examples will be listed below to explain the scheme of the present invention. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. If specific techniques or conditions are not specified in the examples, the techniques or conditions described in the literature in the art or in accordance with the product instructions are used. The reagents or instruments used without indicating the manufacturer are all conventional products that can be obtained commercially. The Viscozyme L and the β-glucanase in the examples are all known products and can be obtained by purchasing commercially available products.
[0055] Example 1 Preparation of a medicinal and edible compound preparation
[0056] The raw materials of the medicinal and edible composition of this embodiment include 9 parts of ginseng and 6 parts of ginger. According to the composition, a medicinal and edible compound preparation is prepared, and the preparation method thereof includes:
[0057] S1. Weigh the above raw materials and dry and crush them, then pass through a 60-mesh sieve to obtain a fine powder;
[0058] S2. The enzyme preparation, water and fine powder are mixed in a mass ratio of 1:1000:100, and the mixture is subjected to enzymatic extraction at 50°C for 2 hours, the mixture is heated to 80°C, and the mixture is extracted again for 1 hour, and then centrifuged at 4500 rpm for 10 minutes and filtered to obtain a filtrate; wherein the enzyme preparation comprises Viscozyme L having a mass concentration of 1% and β-glucanase having a mass concentration of 1%;
[0059] S3. Concentrate, sterilize and spray-dry the filtrate to obtain the product.
[0060] Comparative Example 1
[0061] Example 1 was compared with Reference Example 1, wherein the difference between Reference Example 1 and Example 1 was that the raw materials of the edible and medicinal composition were replaced with 7 parts of ginseng and 8 parts of angelica, and the remaining conditions such as the preparation steps of the edible and medicinal compound preparation and the selection and dosage of the remaining materials were the same as those in Example 1 (compared with Example 1, this reference example used the Chinese medicine composition in the Chinese patent document CN116687987A to replace the edible and medicinal composition of the present invention, to prove that the edible and medicinal composition provided by the present invention has better effect).
[0062] Comparative Example 2
[0063] Example 1 was compared with Control Example 2, wherein Control Example 2 differed from Example 1 in that only 9 portions of ginseng were used, and the remaining preparation steps were the same as those of Example 1 (this Control Example was compared with Example 1 to prove that the medicinal and edible composition provided by the present invention has better effects).
[0064] Comparative Example 3
[0065] Example 1 was compared with Reference Example 3, wherein the difference between Reference Example 3 and Example 1 was that only 6 portions of ginger were used, and the remaining preparation steps were the same as those of Example 1 (this Reference Example was compared with Example 1 to prove that the medicinal and edible composition provided by the present invention has better effect).
[0066] Comparative Example 4
[0067] Example 1 was compared with reference example 4, wherein reference example 4 differed from example 1 in that 9 parts of ginseng and 3 parts of ginger were used, and the remaining preparation steps were the same as those of example 1 (compared with example 1, this reference example is used to prove that the raw material ratio of the medicine-food composition provided by the present invention is better).
[0068] Experimental example
[0069] 1. Experimental animals, grouping and drug treatment
[0070] 90 SPF grade six-week-old male ICR mice, weighing 18-22 g. Animal source: Sbefor (Beijing) Biotechnology Co., Ltd. (Laboratory Animal Production License No.: SCXK (Beijing) 2019-0010). The breeding environment is a barrier environment. This animal experiment was approved by the Experimental Animal Welfare Ethics Committee of Chengdu University of Traditional Chinese Medicine, with the review number 2024048.
[0071] After one week of adaptive feeding, the mice were randomly divided into 9 groups according to body weight, with 10 mice in each group, and the gavage dose (10 mL / kg) was adjusted according to body weight until the 30th day. A blank control group (gavage with normal saline), a model group (gavage with normal saline), a low-dose group (gavage with 0.45 g / kg / day in the embodiment), a medium-dose group (gavage with 0.9 g / kg / day in the embodiment), and a high-dose group (gavage with 1.8 g / kg / day in the embodiment); a first control group (gavage with 0.45 g / kg / day of the compound preparation of control example 1), a second control group (gavage with 0.45 g / kg / day of the compound preparation of control example 2), a third control group (gavage with 0.45 g / kg / day of the compound preparation of control example 3), and a fourth control group (gavage with 0.45 g / kg / day of the compound preparation of control example 4). The dosage of the first, second, third, and fourth control groups was consistent with that of the low-dose group.
[0072] Except for the blank control group, each group of mice was subjected to high-intensity running training every day to establish a fatigue model (5°, 20m / min, 5min). Each group of mice was trained in the Barnes maze from the 25th day after gavage, and a 3-day behavioral experiment was performed on the 28th day to evaluate the effects of the drug on the learning ability and fatigue level of the mice. All the above experiments were conducted in the behavioral laboratory to avoid external interference, and the samples were collected immediately after the behavioral experiment.
[0073] 2. Barnes maze test and T maze test
[0074] Central nervous system fatigue can lead to a decline in learning and memory, and the T-maze and Barnes maze are commonly used learning and memory assessment experiments. Therefore, this study selected these two behavioral experiments to evaluate the effects of ginseng anti-fatigue compound on central nervous system fatigue in fatigued mice.
[0075] The formal test was conducted 3 days after training. The day before the start of training, the mice were placed in the escape box of the target hole to adapt for 4 minutes. During training, the mice were placed in a black box in the center of the maze to restrict their activities for 5 seconds. The black box was removed and the timer was started. If all four limbs of the mouse entered the escape box, it was counted as an escape, and the animal was allowed to stay in the box for 30 seconds. Each animal was observed for a maximum of 4 minutes at a time. If the animal still could not find the target box during this period, the animal was removed from the maze, placed in the escape box and stayed for 30 seconds. Use this interval to clean the maze. The animals were trained once a day for 3 consecutive days. The formal experiment began on the 4th day to observe whether the mice could find the escape box and the latency of finding the target hole.
[0076] The spontaneous continuous alternation experiment method was used, and the formal experiment was carried out 6 hours after the Barnes maze test. First, the animals were allowed to fully adapt to the maze, and then they were placed in the trunk arm, the gate was opened, and they were allowed to freely choose to enter one of the arms. After that, the animals were placed back in the trunk arm again, and the above experiment was repeated 6 times. The number of times the animals entered each arm was recorded. The number of animal alternations during the experiment divided by the total number of choices was used as an evaluation index for memory ability.
[0077] The results are shown in Table 1 and Figure 1 As shown in A, after intervention with low, medium and high doses of the medicinal and edible compound, the hole-finding time of fatigued mice in the Barnes maze was 25.25±12.52s, 23.58±11.30s and 32.54±18.35s, respectively, which was shorter than that of the model group (73.30±32.61s), and the difference was statistically significant (P<0.001), indicating that the medicinal and edible compound of the present invention has the effect of relieving central fatigue.
[0078] Secondly, the low-dose embodiment group has a better effect than the first control group at the same dosage, indicating that the medicine-food compound prescription provided by the present invention is better than the Chinese medicine composition in Chinese patent document CN116687987A in terms of the hole-finding time in the Barnes maze.
[0079] Moreover, compared with the model group, the hole-finding time of the low-dose group was shortened by 48.05 s, which was better than the sum of the improvements of the second and third controls by 23.90 s, indicating that the medicine-food compound provided by the present invention has a synergistic effect on the hole-finding time in the Barnes maze.
[0080] In addition, the hole-finding time of the low-dose group was significantly shorter than that of the control example 4, indicating that the ratio of the medicine-food compound provided by the present invention is better for the hole-finding time in the Barnes maze.
[0081] The results are shown in Table 1 and Figure 1As shown in Figure B, after intervention with low, medium and high doses of the medicinal and edible compound, the correct alternation rates of fatigued mice in the T maze were 64.00±12.65%, 54.00±13.50% and 60.00±16.33%, respectively, which were higher than that of the model group (28.00±13.98%), and the difference was statistically significant (P<0.001), indicating that the medicinal and edible compound of the present invention has the effect of relieving central fatigue.
[0082] Secondly, the low-dose embodiment group had a higher accuracy rate than the first control group at the same dosage, indicating that the medicine-food compound prescription provided by the present invention is superior to the Chinese medicine composition in Chinese patent document CN116687987A in terms of the correct alternation rate in the T-maze.
[0083] Moreover, compared with the model group, the correct alternation rate of the low-dose group increased by 36.00%, which was better than the sum of the increases of the second and third controls (24.00%), indicating that the medicine-food compound provided by the present invention has a synergistic effect on the correct alternation rate in the T-maze.
[0084] In addition, the correct alternation rate of the low dose was significantly higher than that of the control example 4, indicating that the correct alternation rate in the T-maze is better in the proportion of the medicine-food compound provided by the present invention.
[0085] Table 1 Effects of the medicinal and edible compound on the hole-finding time in the Barnes maze and the correct alternation rate in the T maze of fatigued mice
[0086]
[0087] Note: * indicates P < 0.05 compared with the model group; ** indicates P < 0.01 compared with the model group; *** indicates P < 0.001 compared with the model group; **** indicates P < 0.0001 compared with the model group.
[0088] 3. Biochemical index detection
[0089] The contents of γ-aminobutyric acid (GABA), glutamate (Glu), 5-hydroxytryptamine (5-HT) and eNOS in mouse brain tissue were determined using a full-wavelength microplate reader according to the instructions of the kit.
[0090] The Glu / GABA ratio reflects the balance between excitatory and inhibitory neurotransmission, which is essential for synaptic plasticity and information transmission. A lower Glu / GABA ratio may lead to insufficient neuronal activity. 5-HT is an inhibitory neurotransmitter that is essential for the generation and elimination of central fatigue, so an increase in 5-HT can be used to indicate the improvement of central fatigue; while a decrease in eNOS levels may lead to reduced cerebral blood flow and insufficient energy supply, which will affect learning and memory.
[0091] The results are shown in Table 2 and Figure 2 As shown in Figure A, after intervention with low, medium and high doses of the medicinal and edible compound, the Glu / GABA ratios in the mouse brain tissue were 0.82±0.38, 0.72±0.19 and 0.80±0.06, respectively. Compared with the model group (0.33±0.17), the Glu / GABA ratio increased, and the difference was statistically significant (P<0.01), indicating that the medicinal and edible compound of the present invention has the effect of relieving central fatigue.
[0092] Secondly, the low-dose embodiment group has a better effect than the first control group at the same dosage, indicating that the medicine-food compound prescription provided by the present invention is better than the Chinese medicine composition in Chinese patent document CN116687987A for the Glu / GABA ratio in brain tissue.
[0093] Moreover, compared with the model group, the Glu / GABA ratio in the brain tissue increased by 0.49, which was better than the sum of the increases of the second and third controls of 0.40, indicating that the medicinal and edible compound provided by the present invention has a synergistic effect on the Glu / GABA ratio in the brain tissue.
[0094] In addition, the Glu / GABA ratio in the low-dose brain tissue was significantly higher than that in the control example 4, indicating that the ratio of Glu / GABA in the brain tissue is better in the medicine-food compound provided by the present invention.
[0095] The results are shown in Table 2 and Figure 2 As shown in Figure B, after intervention with low, medium and high doses of the medicinal and edible compound, the 5-HT content in the mouse brain tissue was 32.01±6.91, 33.65±5.30 and 32.56±11.47 ng / mL, respectively. Compared with 17.28±4.21 ng / mL in the model group, the 5-HT content in the brain tissue was increased, and the difference was statistically significant (P<0.01), indicating that the medicinal and edible compound of the present invention has the effect of relieving central fatigue.
[0096] Secondly, the low-dose embodiment group has a better effect than the first control group at the same dosage, indicating that the medicine-food compound prescription provided by the present invention is better than the Chinese medicine composition in Chinese patent document CN116687987A for the 5-HT content in brain tissue.
[0097] Moreover, compared with the model group, the 5-HT content in the mouse brain tissue increased by 14.73 ng / mL, which was better than the sum of the increases of the second and third controls, 5.66 ng / mL, indicating that the medicine-food compound provided by the present invention has a synergistic effect on the 5-HT content in brain tissue.
[0098] In addition, the 5-HT content in the brain tissue of the low dose was significantly higher than that of the control example 4, indicating that the ratio of the medicine-food compound provided by the present invention is better for the 5-HT content in the brain tissue.
[0099] The results are shown in Table 2 and Figure 2 As shown in Figure C, after intervention with low and medium doses of the medicinal and edible compound, the eNOS content in the mouse brain tissue was 99.78±30.71 and 90.53±22.17 pg / mL, respectively. Compared with 49.54±29.56 pg / mL in the model group, the eNOS content in the brain tissue was increased, and the difference was statistically significant (P<0.05), indicating that the medicinal and edible compound of the present invention has the effect of relieving central fatigue.
[0100] Secondly, the low-dose embodiment group has a better effect than the first control group at the same dosage, indicating that the medicine-food compound prescription provided by the present invention is better than the Chinese medicine composition in Chinese patent document CN116687987A for the eNOS content in brain tissue.
[0101] Moreover, compared with the model group, the eNOS content in the mouse brain tissue increased by 50.24 pg / mL, which was better than the sum of the increases of the second and third controls (22.32 pg / mL), indicating that the medicine-food compound provided by the present invention has a synergistic effect on the eNOS content in brain tissue.
[0102] In addition, the eNOS content in the brain tissue of the low dose was significantly higher than that of the control example 4, indicating that the ratio of the medicine-food compound provided by the present invention is better for the eNOS content in the brain tissue.
[0103] Table 2 Effects of the medicinal and edible compound on the Glu / GABA ratio, 5-HT and eNOS content in brain tissue of fatigue mice
[0104]
[0105] Note: * indicates P < 0.05 compared with the model group; ** indicates P < 0.01 compared with the model group; *** indicates P < 0.001 compared with the model group; **** indicates P < 0.0001 compared with the model group.
[0106] In summary, the medicine-food compound prescription provided by the present invention has the effect of relieving central fatigue, and its effect is better than the Chinese medicine composition in Chinese patent document CN116687987A, and the prescription components have a synergistic effect. The medicine-food compound provided by the present invention has a better ratio.
[0107] 4. Determination of brain components
[0108] Brain tissue 1 hour after the last gavage was homogenized, internal standard was added, and vortexed for 10 seconds; 300 μL of protein precipitant methanol-acetonitrile (V:V=2:1) was added and vortexed for 1 minute; ultrasonic extraction was performed in an ice-water bath for 10 minutes, and the mixture was allowed to stand at -20°C for 30 minutes and then centrifuged at 4°C and 13,000×g for 10 minutes; 300 μL of supernatant was blown dry with nitrogen gas, and 400 μL of methanol-water (V:V=1:4) was added for re-dissolution, vortexed for 30 seconds, ultrasonicated for 2 minutes, and centrifuged at 4°C and 13,000×g for 10 minutes; 150 μL of supernatant was aspirated with a syringe, filtered using a 0.22 μm organic phase pinhole filter, and transferred to an LC injection vial for UPLC-Q-Tof-MS analysis. The injection volume was 2 μL; mobile phase A was water (containing 0.1% formic acid); mobile phase B was acetonitrile (containing 0.1% formic acid); gradient elution, 0-1.5 min, B: 5%; 1.5-3 min, B: 5%→30%; 3-7 min, B: 30%→60%; 7-9 min, B: 60%→90%; 9-11 min, B: 90%→100%; 11-12 min, B: 100%; 12-15 min, B: 100%→5%; 15-16 min, B: 5%. The flow rate was 0.4 mL / min; the ion source was ESI; the signal was collected in positive and negative ion scanning mode, and the mass spectrometry scanning range was 60-900 amu; the spray voltage was 3,500 V for positive ion scanning; the spray voltage was 3,100 V for negative ion scanning; the auxiliary gas flow rate was 10 Arb; and the capillary temperature was 320 ° C. The collected information was compared and analyzed with databases such as MzCloud, MzValue, PubChem, and ChemSpider and reported literature to determine the brain components of each group of mice.
[0109] Non-targeted metabolomics analysis of brain-entering components of each group of mice showed that 20(S)-protopanaxadiol and panaxatriol may be brain-entering components of ginseng. Therefore, standard products were used to compare the model group, the low-dose example group containing ginseng, the first control group, the second control group, and the fourth control group. The results are shown in Figure 3 As shown in A, no ginsenoside was detected in the brain tissues of mice in each group; Figure 3As shown in Figure B, 20(S)-protopanaxadiol was not detected in the brain tissues of the model group, the first control group, the second control group, and the fourth control group, while 20(S)-protopanaxadiol was detected in the brain tissues of the mice in the low-dose example group, and its content was (1.54±0.56) μg / g. The above research results indicate that the medicine-food compound prescription provided by the present invention can promote the passage of ginseng active ingredients through the blood-brain barrier.
Claims
1. A medicinal and edible composition for relieving central nervous system fatigue, characterized in that: The raw materials of the composition include 4.5 to 18 parts of ginseng and 3 to 12 parts of ginger by weight.
2. A medicinal and edible preparation for relieving central nervous system fatigue, characterized in that: The medicine-food composition is prepared from the medicine-food composition according to claim 1.
3. The medicine-food homologous preparation according to claim 2, characterized in that: The dosage form of the preparation includes at least one of a decoction piece, a decoction, a powder, an oral liquid, an ointment, a granule, a tablet, a capsule or an alcoholic preparation.
4. A method for preparing the medicine-food homologous preparation according to claim 2 or 3, characterized in that: The following steps are involved: The raw material is first dried, crushed and sieved to obtain fine powder; The enzyme preparation, water and the fine powder are mixed, and the mixture is subjected to heat preservation and enzymatic extraction, and then the temperature is increased for re-extraction, and then centrifuged and filtered to obtain a filtrate; Finally, the filtrate is concentrated, sterilized and subjected to a second drying to obtain a medicine-food preparation.
5. The method according to claim 4, characterized in that The enzyme preparation includes Viscozyme L and β-glucanase.
6. The method according to claim 4, characterized in that The mass ratio of the enzyme preparation, water and fine powder is 1:500-1000:50-100.
7. The method according to claim 4, characterized in that The temperature of the heat preservation enzymatic extraction is 45 to 55° C., and the time of the heat preservation enzymatic extraction is 1 to 3 hours; And / or, the temperature of the re-extraction is 75-85° C., and the time of the re-extraction is 1-3 hours.
8. The method according to claim 4, characterized in that The screening includes: passing through a 40-60 mesh sieve.
9. Use of the edible-medicine composition according to claim 1, or the edible-medicine preparation according to claim 2 or 3, or the method according to any one of claims 4 to 8 in the preparation of medicines and / or health products and / or foods for improving central fatigue.
Citation Information
Patent Citations
Traditional Chinese medicine composition as well as preparation method and application thereof
CN116687987A
Ginseng and ginger juice health-care milk beverage and making method thereof
CN107865100A
Red ginseng product of wild ginseng and preparation method of red ginseng product
CN108478613A
Medicinal and edible traditional Chinese medicine composition and application thereof
CN111743066A
Anti-fatigue medicinal and edible composition and application thereof
CN115444922A
